Rezolute validates RZ358 for NICTH, doubling addressable tumor HI patient population

Rezolute, Inc.

Preclinical study shows RZ358 blunts IGF-2 and insulin-mediated signaling at clinically relevant levels.
Total addressable US market for tumor HI est. at ~4,500 patients (1,500 ICTH + 3,000 NICTH).
Company evaluating registrational study in tumor HI including both ICTH and NICTH after positive Jan 2024 FDA interaction.
RZ358 already in Phase 3 for congenital HI; has Orphan Drug Designations in US/EU for multiple indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.